Krystal Biotech, Inc. - Common Stock (KRYS)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Mar 30, 2026Investment Snapshot
- Trading 222% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 14.8% — below-average profitability
- Revenue growing at 34% annually
Krystal Biotech, Inc. - Common Stock (KRYS) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $7.2 billion . Key value metrics: P/E ratio 39.7, P/B ratio 5.88, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Krystal Biotech, Inc. - Common Stock — Fundamental Analysis Summary
Krystal Biotech, Inc. - Common Stock (KRYS) is currently trading 222% above its Graham Number of $76.16, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 39.7x.
On financial health, KRYS shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 14.8% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.09.
StockPik's composite Value Score for KRYS is 42/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
KRYS shows revenue growing at 34% year-over-year, with earnings growing at 130%.